161 related articles for article (PubMed ID: 24259624)
1. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
2. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
Gosselin R; Hawes E; Moll S; Adcock D
Am J Clin Pathol; 2014 Feb; 141(2):262-7. PubMed ID: 24436275
[TBL] [Abstract][Full Text] [Related]
3. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
4. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
Jaffer IH; Chan N; Roberts R; Fredenburgh JC; Eikelboom JW; Weitz JI
J Thromb Haemost; 2017 Dec; 15(12):2377-2387. PubMed ID: 28976630
[TBL] [Abstract][Full Text] [Related]
6. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods.
Du S; Weiss C; Christina G; Krämer S; Wehling M; Krämer R; Harenberg J
Clin Chem Lab Med; 2015 Jul; 53(8):1237-47. PubMed ID: 25720084
[TBL] [Abstract][Full Text] [Related]
7. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
8. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Montaruli B; Erroi L; Vitale C; Berutti S; Cosseddu D; Sivera P; Coglitore R; Marangella M; Migliardi M
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):225-9. PubMed ID: 25629417
[TBL] [Abstract][Full Text] [Related]
11. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
12. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
13. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
14. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study.
de Fautereau-Vassel A; Mokhtarian A; Mangenot M; Krekounian O; Kousignian I; Delavenne X; Curis E; Gouin-Thibault I; Siguret V
Int J Lab Hematol; 2024 Feb; 46(1):120-127. PubMed ID: 37710085
[TBL] [Abstract][Full Text] [Related]
15. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
17. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
Delavenne X; Moracchini J; Laporte S; Mismetti P; Basset T
J Pharm Biomed Anal; 2012 Jan; 58():152-6. PubMed ID: 21996066
[TBL] [Abstract][Full Text] [Related]
18. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
19. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
